Current status and recent advances in the application of mini-invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer

Cui Hao; Wei Bo

doi:10.3969/j.issn.1003-5591.2024.04.001

您当前的位置：

首页 >

文章列表页 >

Current status and recent advances in the application of mini-invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer

更新时间：2026-11-05

- Current status and recent advances in the application of mini-invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer
- J Abdominal Surg Vol. 37, Issue 4, Pages: 231-236(2024)
- 作者机构：
  
  1.解放军总医院第一医学中心普通外科医学部，北京 100853
  2.南开大学医学院，天津 300071
- 作者简介：
  
  Wei Bo， Email： weibo@vip.163.com
- 基金信息：
- DOI：10.3969/j.issn.1003-5591.2024.04.001
  CLC： R656
- Received：05 August 2024，
  
  Published：22 August 2024
- 稿件说明：
移动端阅览
崔昊,卫勃.局部进展期胃癌新辅助免疫治疗后微创外科治疗的应用现状与进展[J].腹部外科,2024,37(04):231-236.

Cui Hao,Wei Bo.Current status and recent advances in the application of mini-invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer[J].J Abdominal Surg,2024,37(04):231-236.
崔昊,卫勃.局部进展期胃癌新辅助免疫治疗后微创外科治疗的应用现状与进展[J].腹部外科,2024,37(04):231-236. DOI： 10.3969/j.issn.1003-5591.2024.04.001.

Cui Hao,Wei Bo.Current status and recent advances in the application of mini-invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer[J].J Abdominal Surg,2024,37(04):231-236. DOI： 10.3969/j.issn.1003-5591.2024.04.001.

摘要

新辅助免疫治疗已成为提升局部进展期胃癌（locally advanced gastric cancer， LAGC）治疗效果的有效方式。在微创外科时代，新辅助免疫治疗带来的良好肿瘤学响应、治疗相关不良事件及对术区组织的潜在影响与围手术期安全性及远期生存关系密切。现有证据认为LAGC新辅助免疫治疗后行微创手术尽管操作难度较大，但整体安全可行，远期生存相当。在此基础上，应积极推动临床合作，聚焦新辅助免疫治疗后手术时机选择、淋巴结个体化清扫、功能保留性微创手术等关键问题，以规范及拓展微创手术在LAGC新辅助免疫治疗后外科治疗的适应证。

Abstract

Neoadjuvant immunotherapy has become an effective modality for enhancing the therapeutic efficacy of locally advanced gastric cancer （LAGC）. In modern era of mini-invasive surgery， favorable tumor response， treatment-related adverse events and potential impact on perioperative tissues from neoadjuvant immunotherapy are correlated closely with perioperative safety and long-term survival. Current evidence suggests that mini-invasive gastrectomy after neoadjuvant immunotherapy is both safe and feasible with comparable short-term outcomes and long-term survival despite intraoperative difficulties. On this basis， clinical cooperation should be actively promoted for addressing such key issues as timing of surgery after neoadjuvant immunotherapy， individualized lymph node dissection and function-preserving mini-invasive gastrectomy to standardize and expand the indications for mini-invasive gastrectomy after neoadjuvant immunotherapy for LAGC.

关键词

Keywords

references

Han BF ， Zheng RS ， Zeng HM ， et al . Cancer incidence and mortality in China，2022 ［J］. J Natl Cancer Cent ， 2024 ， 4 （ 1 ）： 47 - 53 . DOI： 10.1016/j.jncc.2024.01.006 http://dx.doi.org/10.1016/j.jncc.2024.01.006 .

Cunningham D ， Allum WH ， Stenning SP ， et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer ［J］. N Engl J Med ， 2006 ， 355 （ 1 ）： 11 - 20 . DOI： 10.1056/NEJMoa055531 http://dx.doi.org/10.1056/NEJMoa055531 .

Liu TS ， Bai YX ， Lin XY ， et al . First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric，gastroesophageal junction and esophageal adenocarcinoma：CheckMate 649 Chinese subgroup analysis ［J］. Int J Cancer ， 2023 ， 152 （ 4 ）： 749 - 760 . DOI： 10.1002/ijc.34296 http://dx.doi.org/10.1002/ijc.34296 .

Xu JM ， Jiang HP ， Pan YY ， et al . Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer：the ORIENT-16 randomized clinical trial ［J］. JAMA ， 2023 ， 330 （ 21 ）： 2064 - 2074 . DOI： 10.1001/jama.2023.19918 http://dx.doi.org/10.1001/jama.2023.19918 .

Qiu MZ ， Oh DY ， Kato K ， et al . Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma：RATIONALE-305 randomised，double blind，phase 3 trial ［J］. BMJ ， 2024 ， 385 ： e078876 . DOI： 10.1136/bmj-2023-078876 http://dx.doi.org/10.1136/bmj-2023-078876 .［PubMed］

Shitara K ， Rha SY ， Wyrwicz LS ， et al . LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer ［J］. Ann Oncol ， 2024 ， 35 ： S213 . DOI： 10.1016/j.annonc.2024.06.007 http://dx.doi.org/10.1016/j.annonc.2024.06.007 .

Janjigian YY ， Al-Batran SE ， Wainberg ZA ， et al . Pathological complete response （pCR） to 5-fluorouracil，leucovorin，oxaliplatin and docetaxel （FLOT） with or without durvalumab （D） in resectable gastric and gastroesophageal junction cancer （GC/GEJC）：Subgroup analysis by region from the phase 3，randomized，double-blind MATTERHORN study ［J］. J Clin Oncol ， 2024 ， 42 （ 3_suppl ）： LBA246 . DOI： 10.1200/jco.2024.42.3_suppl.lba246 http://dx.doi.org/10.1200/jco.2024.42.3_suppl.lba246 .

丁学伟，梁寒 . 免疫治疗在局部进展期胃癌围手术期治疗的初步探索［J］. 腹部外科， 2024 ， 37 （ 2 ）： 81 - 85 . DOI： 10.3969/j.issn.1003-5591.2024.02.001 http://dx.doi.org/10.3969/j.issn.1003-5591.2024.02.001 .

Li ZY ， Shan F ， Ying XJ ， et al . Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer：a randomized clinical trial ［J］. JAMA Surg ， 2019 ， 154 （ 12 ）： 1093 - 1101 . DOI： 10.1001/jamasurg.2019.3473 http://dx.doi.org/10.1001/jamasurg.2019.3473 .

Tian Y ， Guo HH ， Hu YY ， et al . Safety and efficacy of robotic-assisted versus laparoscopic distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer ［J］. Surg Endosc ， 2023 ， 37 （ 9 ）： 6761 - 6770 . DOI： 10.1007/s00464-023-10122-w http://dx.doi.org/10.1007/s00464-023-10122-w .

Su J ， Guo WH ， Chen ZA ， et al . Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy：a retrospective cohort study ［J］. Front Immunol ， 2022 ， 13 ： 1078196 . DOI： 10.3389/fimmu.2022.1078196 http://dx.doi.org/10.3389/fimmu.2022.1078196 .

吕剑波，尹玉平，张鹏，等 . 新辅助化疗联合免疫治疗后腹腔镜胃癌根治术的安全性分析［J］. 中华胃肠外科杂志， 2023 ， 26 （ 1 ）： 84 - 92 . DOI： 10.3760/cma.j.cn441530-20220616-00265 http://dx.doi.org/10.3760/cma.j.cn441530-20220616-00265 .

Sun YQ ， Zhong Q ， Lv CB ， et al . The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer：a multicenter Real-world clinical study ［J］. Int J Surg ， 2024 ，Apr 23 . DOI： 10.1097/JS9.0000000000001468 http://dx.doi.org/10.1097/JS9.0000000000001468 .

Cui H ， Liang WQ ， Cui JX ， et al . Safety and feasibility of minimally invasive gastrectomy after neoadjuvant immunotherapy for locally advanced gastric cancer：a propensity score-matched analysis in China ［J］. Gastroenterol Rep （Oxf）， 2024 ， 12 ： goae005 . DOI： 10.1093/gastro/goae005 http://dx.doi.org/10.1093/gastro/goae005 .

邵欣欣，李维坤，胡海涛，等 . 化疗联合免疫和靶向新辅助治疗后腹腔镜胃癌根治术的疗效及安全性［J］. 中华医学杂志， 2024 ， 104 （ 16 ）： 1397 - 1402 . DOI： 10.3760/cma.j.cn112137-20230811-00206 http://dx.doi.org/10.3760/cma.j.cn112137-20230811-00206 .

Lin JL ， Lin M ， Lin GT ， et al . Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion ［J］. Front Immunol ， 2024 ， 15 ： 1322152 . DOI： 10.3389/fimmu.2024.1322152 http://dx.doi.org/10.3389/fimmu.2024.1322152 .

Cui H ， Yuan Z ， Liang WQ ， et al . Safety and efficacy of minimally invasive gastrectomy for older patients with gastric cancer after neoadjuvant chemotherapy and immunotherapy：a propensity score-matched analysis ［J］. BMC Geriatr ， 2024 ， 24 （ 1 ）： 606 . DOI： 10.1186/s12877-024-05193-w http://dx.doi.org/10.1186/s12877-024-05193-w .

Jiang Q ， Liu WZ ， Zeng XY ， et al . Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer：real-world experience with a consecutive patient cohort ［J］. Front Immunol ， 2023 ， 14 ： 1122121 . DOI： 10.3389/fimmu.2023.1122121 http://dx.doi.org/10.3389/fimmu.2023.1122121 .

Wang XX ， Lu CR ， Wei B ， et al . Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer （RESONANCE）：a randomized，open-label，phase 3 trial ［J］. J Hematol Oncol ， 2024 ， 17 （ 1 ）： 17 . DOI： 10.1186/s13045-024-01536-7 http://dx.doi.org/10.1186/s13045-024-01536-7 .

崔昊，张珂诚，卫勃，等 . 新辅助免疫治疗在局部进展期胃癌外科治疗的应用现状与挑战［J］. 国际外科学杂志， 2023 （ 5 ）： 289 - 294 . DOI： 10.3760/cma.j.cn431274-20210928-01025 http://dx.doi.org/10.3760/cma.j.cn431274-20210928-01025 .

Xu Y ， Lyu XH ， Qin YZ ， et al . Multi-organs perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC ［J］. Thorac Cancer ， 2022 ， 13 （ 16 ）： 2340 - 2345 . DOI： 10.1111/1759-7714.14567 http://dx.doi.org/10.1111/1759-7714.14567 .

van der Wielen N ， Brenkman H ， Seesing M ， et al . Minimally invasive versus open gastrectomy for gastric cancer.A pooled analysis of two European randomized controlled trials ［J］. J Surg Oncol ， 2024 ， 129 （ 5 ）： 911 - 921 . DOI： 10.1002/jso.27578 http://dx.doi.org/10.1002/jso.27578 .

Davey MG ， Temperley HC ， O’Sullivan NJ ， et al . Minimally invasive and open gastrectomy for gastric cancer：a systematic review and network meta-analysis of randomized clinical trials ［J］. Ann Surg Oncol ， 2023 ， 30 （ 9 ）： 5544 - 5557 . DOI： 10.1245/s10434-023-13654-6 http://dx.doi.org/10.1245/s10434-023-13654-6 .

Bhandare MS ， Gundavda KK ， Yelamanchi R ， et al . Impact of pCR after neoadjuvant chemotherapy and radical D2 dissection in locally advanced gastric cancers：Analysis of 1001 cases ［J］. Eur J Surg Oncol ， 2024 ， 50 （ 6 ）： 108343 . DOI： 10.1016/j.ejso.2024.108343 http://dx.doi.org/10.1016/j.ejso.2024.108343 .

Association JGC . Japanese gastric cancer treatment guidelines 2021 （6th edition）［J］. Gastric Cancer ， 2023 ， 26 （ 1 ）： 1 - 25 . DOI： 10.1007/s10120-022-01331-8 http://dx.doi.org/10.1007/s10120-022-01331-8 .

Salvador-Rosés H ， Escartín A ， Muriel P ， et al . Robotic versus open approach in total gastrectomy for gastric cancer：a comparative single-center study of perioperative outcomes ［J］. J Robot Surg ， 2023 ， 17 （ 4 ）： 1735 - 1741 . DOI： 10.1007/s11701-023-01591-1 http://dx.doi.org/10.1007/s11701-023-01591-1 .

Rahim MK ， Okholm TLH ， Jones KB ， et al . Dynamic CD8 + T cell responses to cancer immunotherapy in human regional lymph nodes are disrupt ed in metastatic lymph nodes ［J］. Cell ， 2023 ， 186 （ 6 ）： 1127 - 1143.e18 . DOI： 10.1016/j.cell.2023.02.021 http://dx.doi.org/10.1016/j.cell.2023.02.021 .

Kang YK ， Terashima M ， Kim YW ， et al . Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection （ATTRACTION-5）：a randomised，multicentre，double-blind，placebo-controlled，phase 3 trial ［J］. Lancet Gastroenterol Hepatol ， 2024 ， 9 （ 8 ）： 705 - 717 . DOI： 10.1016/S2468-1253（24）00156-0 http://dx.doi.org/10.1016/S2468-1253（24）00156-0 .

Yuan Z ， Cui H ， Xu QX ， et al . Total versus proximal gastrectomy for proximal gastric cancer after neoadjuvant chemotherapy：a multicenter retrospective propensity score-matched cohort study ［J］. Int J Surg ， 2024 ， 110 （ 2 ）： 1000 - 1007 . DOI： 10.1097/JS9.0000000000000927 http://dx.doi.org/10.1097/JS9.0000000000000927 .

Gu TF ， Wang YK ， Wu ZQ ， et al . Feasibility and long-term survival of proximal gastrectomy after neoadjuvant therapy for locally advanced proximal gastric cancer：a propensity-score-matched analysis ［J］. Chin Med J （Engl）， 2024 ，Aug 2 . DOI： 10.1097/CM9.0000000000003232 http://dx.doi.org/10.1097/CM9.0000000000003232 .

崔昊，卫勃 . 功能保留性胃切除术后消化道重建术式的分类及选择策略［J］. 中华胃肠外科杂志， 2021 ， 24 （ 5 ）： 392 - 396 . DOI： 10.3760/cma.j.issn.441530-20210305-00101 http://dx.doi.org/10.3760/cma.j.issn.441530-20210305-00101 .

林书萌，刘合利，杨廷，等 . 辩题一：胃癌新辅助化疗2～3 程有效后应继续化疗还是尽快手术［J］. 中华胃肠外科杂志， 2024 ， 27 （ 7 ）： 678 - 680 . DOI： 10.3760/cma.j.cn441530-20240508-00171 http://dx.doi.org/10.3760/cma.j.cn441530-20240508-00171 .

中华医学会外科学分会腹腔镜与内镜外科学组，中国研究型医院学会机器人与腹腔镜外科专业委员会，中国抗癌协会腔镜与机器人外科分会，等 . 腹腔镜胃癌手术操作指南（2023版）［J］. 中华消化外科杂志， 2023 ， 22 （ 4 ）： 425 - 436 . DOI： 10.3760/cma.j.cn115610-20230317-00113 http://dx.doi.org/10.3760/cma.j.cn115610-20230317-00113 .

卫勃，崔昊，宋立强 . 腹腔镜手术在晚期胃癌中应用争议与共识［J］. 中国实用外科杂志， 2023 ， 43 （ 9 ）： 993 - 997 . DOI： 10.19538/j.cjps.issn1005-2208.2023.09.08 http://dx.doi.org/10.19538/j.cjps.issn1005-2208.2023.09.08 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

局部进展期胃癌新辅助化疗联合免疫治疗术后复发模式及预后

Research advances of immunotherapy for gastric cancer

Current status and future prospects of tumor-associated macrophages and PD-1/PD-L1 in gastric cancer immunotherapy

Effect of neoadjuvant therapy on perioperative complications in patients undergoing laparoscopic radical gastrectomy

Preliminary exploration of perioperative immunotherapy for locally advanced gastric cancer

Related Author

Yin Yuping

Sun Xiong

Ding Jianing

Li Tianhao

Wu Ke

Liu Ke

Li Anshu

Shuai Xiaoming

Related Institution

Department of Gastrointestinal Surgery， Affiliated Jingzhou Hospital， Yangtze University

Department of General Surgery， Third Hospital of Shanxi Medical University， Shanxi Bethune Hospital， Shanxi Academy of Medical Sciences， Tongji Shanxi Hospital

Ward I， Gastrointestinal Cancer Center， Peking University Cancer Hospital

Department of Gastroenterological Surgery， Tianjin Medical University Cancer Institute & Hospital， National Clinical Research Center for Cancer， Municipal Clinical Research Center for Cancer， Municipal Key Laboratory of Digestive Cancer

AI问答

⁰